Quang X. Pham, the Chief Executive Officer and Chairman of Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), has completed a series of stock sales amounting to $36,209. The divestments were executed over three consecutive days, spanning from June 3 to June 5, 2026. The weighted average prices for these transactions ranged from $4.26 to $4.42 per share.
Mr. Pham conducted these sales under a Rule 10b5-1 trading arrangement, which he initially adopted on September 25, 2025. The specific breakdown of the sales includes the following details:
- On June 3, 2026, Mr. Pham sold 2,323 shares at a weighted average price of $4.26.
- On June 4, 2026, he sold an additional 3,898 shares at a weighted average price of $4.41.
- On June 5, 2026, he sold 2,064 shares at a weighted average price of $4.42.
Following these transactions, Mr. Pham's direct holding in Cadrenal Therapeutics common stock stands at 173,224 shares. Furthermore, he holds an indirect interest in 200,000 shares through The PVBQ Living Trust, where he serves as the trustee.
The company's stock is currently trading near its 52-week low of $4.14. Over the past year, the stock has experienced a significant decline of 70%. Despite this downturn, analysis suggests that the company may be undervalued at current levels, with detailed Fair Value metrics available to subscribers.
In other recent developments, Cadrenal Therapeutics reported a net loss of $3.0 million for the fourth quarter ending December 31, 2025. This represents an improvement from the $4.2 million loss recorded in the same period of 2024. The company has also completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding its investigational treatment, CAD-1005, for heparin-induced thrombocytopenia (HIT). Cadrenal plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 trial, which will include approximately 120 patients worldwide. The FDA provided guidance on various aspects of the trial, including protocol design, study population, and safety database. This trial is intended to support a projected New Drug Application submission in 2029. The primary endpoint for the study will focus on new or worsening thrombotic events. Cadrenal is currently incorporating FDA feedback into its Phase 3 protocol. These developments mark significant progress in the company's efforts to address HIT.
Cadrenal Therapeutics Inc.
Analyze CVKD
Included in our AI-picked strategies
Review strategies
4.44
+0.1300
(+3.02%)
Closed
4.52
+0.0800
(+1.80%)
After Hours
16:30:01
1D
1W
1M
6M
1Y
5Y
Max
Created with Highcharts 11.4.8
14:00
15:00
15:30
16:30
18:00
19:00
19:30
4.35
4.4
4.45
4.5
Analyze CVKD
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Is CVKD a bargain right now?
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy.
Get the bottom line for CVKD plus thousands of other stocks and find your next hidden gem with massive upside.
See Undervalued Stocks